字号·· | 护眼
路透社

Cencora将以24亿美元收购美国肿瘤网络Cencora to acquire American Oncology Network in $2.4 billion deal

点「原文对照」整页切到原文,或双击某段只看那段的原文。

Cencora将收购美国肿瘤网络,以加强对社区肿瘤学的支持。通过增加互补能力并扩展至另外十二个州,此举建立在Cencora的MSO平台之上。“收购AON将扩大我们由医生主导的肿瘤学MSO以及对全国各社区医疗护理的支持,”AON表示,其已建立了一个由医生主导的模式,正在重塑社区肿瘤学的提供方式,并且“我们的医生、临床医生和护理团队,以及他们所服务的患者,始终是AON的核心,这项协议旨在为他们提供更多支持、更多资源以及更多用于患者护理的时间,”表示。

Cencora to Acquire American Oncology Network to Strengthen Support of Community Oncology Builds on Cencora’s MSO platform by adding complementary capabilities and expanding presence across twelve additional states“The acquisition of AON will expand our physician-led oncology MSO and support of care in communities across the country,” said AON has built a physician-led model that is reshaping how community oncology is delivered, and“Our physicians, clinicians and care teams, and the patients they serve, have always been at the heart of AON, and this agreement is about giving them more support, more resources and more time for patient care,” said“For patients facing a cancer diagnosis, ensuring dependable access to advanced and innovative therapy is crucial to their survival,” said Stephen “Fred” Divers, M.D., Chief Medical Officer of Transaction Overview As it relates to Cencora’s cash outlay at the time of closing, certain AON stockholders may participate in an equity rollover representing up to 25% of AON.

“对于面临癌症诊断的患者来说,确保可靠地获得先进和创新的治疗对其生存至关重要,”Stephen “Fred” Divers医学博士、交易概述首席医疗官表示。就Cencora在交割时的现金支出而言,某些AON股东可能参与代表AON最多25%的股权展期。假设这些股东通过股权展期保留AON 25%的股权,该交易须满足惯常交割条件,包括获得所需的监管批准和AON股东批准。

该协议已由AON董事会批准,董事会是根据AON独立且无利害关系董事特别委员会的一致建议行事。

Assuming these stockholders retain 25% of AON through the equity rollover, The transaction is subject to the satisfaction of customary closing conditions, including receipt of required regulatory clearances and AON stockholder approvals. The agreement has been approved by AON’s Board of Directors, acting on the unanimous recommendation of AON’s special committee of independent and disinterested directors.

花旗担任Cencora 2026财年预期业绩的首席财务顾问。Cencora 2026财年预期业绩(按调整后非GAAP基准计算)。关于美国肿瘤网络。美国肿瘤网络(AON)是由医生和经验丰富的医疗行业领袖组成的联盟,致力于合作确保社区肿瘤及其他专科的长期成功与可持续发展。AON成立于2018年,其快速扩张的网络代表着在21个州执业的350多名医疗服务提供者。

Citi is serving as lead financial advisor to Cencora’s Fiscal Year 2026 Expectations Cencora’s Fiscal Year 2026 Expectations on an Adjusted (non-GAAP) Basis About About American Oncology Network American Oncology Network (AON) is an alliance of physicians and seasoned healthcare leaders partnering to ensure the long-term success and viability of community oncology and other specialties. Founded in 2018, AON’s rapidly expanding network represents more than 350 providers practicing across 21 states. AON pioneers innovative healthcare solutions through its physician-led model, fostering value-based care that improves patient outcomes while reducing costs and expanding access to quality care.

AON通过其医生主导的模式开创创新医疗解决方案,推动基于价值的医疗服务,在改善患者治疗效果的同时降低成本并扩大优质医疗服务的可及性。AON为其网络内的医生提供独立发展所需的工具,同时提供全面支持、多元化的综合辅助服务以及诊所管理专业知识,使医生能够专注于最重要的事情——为每位患者提供最高标准的医疗服务。

AON equips its network physicians with the tools they need to thrive independently while providing comprehensive support, integrated revenue-diversifying ancillary services, and practice management expertise, enabling physicians to focus on what matters most – providing the highest standard of care for every patient.

AON致力于通过解决癌症治疗中的差异、确保所有患者都能获得所需的医疗服务以实现最佳健康结果,来促进健康公平。AON专注于创新与合作,正在塑造社区肿瘤学的未来。如需了解更多信息,请访问AONcology.com,或在领英、脸书、X(原推特)和YouTube上关注我们。

AON is committed to promoting health equity by addressing disparities in cancer care and ensuring that all patients have access to the care they need to achieve optimal health outcomes. With a focus on innovation and collaboration, AON is shaping the future of community oncology. For more information, please visit AONcology.com or follow us on LinkedIn, Facebook, X (formerly Twitter) and YouTube.

Cencora关于前瞻性陈述的警示说明本新闻稿中某些陈述属于经修订的1933年《证券法》第27A条以及经修订的1934年《证券交易法》(“《证券交易法》”)第21E条所指的“前瞻性陈述”。此类前瞻性陈述可能包括但不限于:关于与AON拟议交易(“拟议交易”)的陈述、完成拟议交易的预期时间表、拟议交易的益处、Cencora和AON的未来机遇,以及有关Cencora或AON未来运营、财务或经营业绩、预期业务水平、未来收益、计划活动、预期增长、市场机遇、战略及其他未来期间预期的任何其他陈述。

Cencora’s Cautionary Note Regarding Forward-Looking Statements Certain of the statements contained in this press release are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the “Securities Exchange Act”). Such forward-looking statements may include, without limitation, statements about the proposed transaction with AON (the “proposed transaction”), the expected timetable for completing the proposed transaction, the benefits of the proposed transaction, future opportunities for Cencora and AON and any other statements regarding Cencora’s or AON’s future operations, financial or operating results, anticipated business levels, future earnings, planned activities, anticipated growth, market opportunities, strategies, and other expectations for future periods. Words such as “aim,” “anticipate,” “believe,” “can,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “on track,” “opportunity,” “plan,” “possible,” “potential,” “predict,” “project,” “seek,” “should,” “strive,” “sustain,” “synergy,” “target,” “will,” “would” and similar expressions are intended to identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. These statements are based on management’s current expectations and are subject to uncertainty and changes in circumstances and speak only as of the date hereof. These statements are not guarantees of future performance and are based on assumptions and estimates that could prove incorrect or could cause actual results to vary materially from those indicated.

“旨在”、“预期”、“相信”、“能够”、“继续”、“可能”、“估计”、“期望”、“打算”、“或可”、“也许”、“按计划推进”、“机遇”、“计划”、“有可能”、“潜在”、“预测”、“预计”、“寻求”、“应当”、“努力”、“维持”、“协同效应”、“目标”、“将会”、“将”及类似表述旨在标识前瞻性陈述,但缺少这些词语并不意味着某项陈述不是前瞻性陈述。

Because forward-looking statements inherently involve risks and uncertainties, actual future results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to: the parties’ ability to meet expectations regarding the timing of the proposed transaction; the parties’ ability to consummate the proposed transaction when expected or at all because required regulatory, stockholder, or other approvals or other conditions to closing are not received or satisfied on the anticipated schedule or at all (and the risk that such approvals may result in the imposition of conditions that could adversely affect Cencora or AON or the expected benefits of the proposed transaction); inherent uncertainties involved in the estimates and judgments used in the preparation of financial statements and the providing of estimates of financial measures, in accordance with GAAP and related standards, or on an adjusted basis; Cencora’s or AON’s failure to achieve expected or targeted future financial and operating performance and results; the possibility that Cencora may be unable to achieve expected benefits, synergies and operating efficiencies in connection with the proposed transaction within the expected time frames or at all; the ability to promptly and effectively integrate the businesses of AON with those of Cencora; the possibility that the proposed transaction may be more expensive to complete than anticipated, including as a result of unexpected factors or events; business disruption being greater than expected following the proposed transaction; the recruiting and retention of key employees being more difficult following the proposed transaction; the effect of any changes in customer and supplier relationships and customer purchasing patterns; the impacts of competition; changes in the economic and financial conditions of the business of Cencora or AON; the occurrence of any event, change, or other circumstance that could give rise to the right of Cencora or AON to terminate the definitive agreement governing the terms and conditions of the proposed transaction; the outcome of any legal proceedings that may be instituted against Cencora or AON; Cencora’s de-leveraging plans and the ability of Cencora to maintain its investment grade rating; and uncertainties and matters beyond the control of management and other factors described under “Risk Factors” in Cencora’s Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and other filings with the SEC.

这些陈述基于管理层当前的预期,受不确定性和情况变化的影响,且仅截至本新闻稿发布之日有效。这些陈述并非对未来业绩的保证,而是基于可能被证明不正确、或可能导致实际结果与所述内容存在重大差异的假设和估计。由于前瞻性陈述本身涉及风险和不确定性,实际未来结果可能与此类前瞻性陈述所明示或暗示的内容存在重大差异。

You can access Cencora’s filings with the SEC through the SEC website at www.sec.gov or through Cencora’s website, and Cencora strongly encourages you to do so. Except as required by applicable law, Cencora undertakes no obligation to update any statements herein for revisions or changes after the date of this communication.

可能导致或促成此类差异的因素包括但不限于:双方能否在拟议交易的时间安排方面达到预期;双方能否按预期时间或根本无法完成拟议交易,原因是所需的监管、股东或其他批准或交割的其他条件未能按预期时间表获得或满足(以及此类批准可能导致施加可能对Cencora或AON或拟议交易的预期收益产生不利影响的条件的风险);按照GAAP及相关标准或按调整后基准编制财务报表和提供财务指标估计时所使用的估计和判断所固有的不确定性;Cencora或AON未能实现预期或目标未来财务和经营业绩及结果;Cencora可能无法在预期时间框架内或根本无法实现与拟议交易相关的预期收益、协同效应和运营效率的可能性;能否迅速有效地将AON的业务与Cencora的业务整合;拟议交易完成成本可能高于预期的可能性,包括由于意外因素或事件所致;拟议交易完成后业务中断程度大于预期;拟议交易完成后招聘和留住关键员工更加困难;客户和供应商关系以及客户购买模式发生任何变化的影响;竞争的影响;Cencora或AON业务的经济和财务状况发生变化;发生任何可能使Cencora或AON有权终止管辖拟议交易条款和条件的最终协议的事件、变化或其他情况交易;针对Cencora或AON提起的任何法律诉讼的结果;Cencora的去杠杆计划以及Cencora维持其投资级评级的能力;以及管理层无法控制的不确定性和事项,以及Cencora在Form 10-K年度报告、Form 10-Q季度报告及其他向SEC提交的文件中“风险因素”部分所述的其他因素。

This press release is neither an offer to sell nor a solicitation of an offer to buy any securities of Cencora. Any such offer will only be made pursuant to a prospectus filed with the SEC or pursuant to one or more exemptions from the registration requirements of the Securities Act of 1933, as amended.

您可以通过SEC网站www.sec.gov或Cencora网站查阅Cencora向SEC提交的文件,Cencora强烈建议您这样做。除适用法律要求外,Cencora不承担在本通讯日期之后因修订或变化而更新本文中任何陈述的义务。

SUPPLEMENTAL INFORMATION REGARDING NON-GAAP FINANCIAL MEASURE To supplement the financial measures prepared in accordance with U.S. generally accepted accounting principles (GAAP), Cencora uses the non-GAAP financial measure described below. The non-GAAP financial measure should be viewed in addition to, and not in lieu of, financial measures calculated in accordance with GAAP. This supplemental measure may vary from, and may not be comparable to, similarly titled measures by other companies.

本新闻稿既不是出售要约,也不是购买Cencora任何证券的要约邀请。任何此类要约仅将依据向SEC提交的招股说明书或依据经修订的1933年《证券法》注册要求的一项或多项豁免作出。

The non-GAAP financial measure is presented because management uses non-GAAP financial measures to evaluate Cencora’s operating performance, to perform financial planning, and to determine incentive compensation. Therefore, Cencora believes that the presentation of the non-GAAP financial measure provides useful supplementary information to, and facilitates additional analysis by, investors. The presented non-GAAP financial measure excludes items that management does not believe reflect Cencora’s core operating performance because such items are outside the control of Cencora or are inherently unusual, non-operating, unpredictable, non-recurring, or non-cash.

关于非GAAP财务指标的补充信息 为补充按照美国公认会计原则(GAAP)编制的财务指标,Cencora使用下述非GAAP财务指标。非GAAP财务指标应与按照GAAP计算的财务指标一并考虑,而不应替代后者。这一补充指标可能与其他公司同类名称的指标不同,且可能无法与之比较。

Cencora does not provide a reconciliation for this non-GAAP financial measure on a forward-looking basis to the most comparable GAAP financial measure on a forward-looking basis because it is unable to provide a meaningful or accurate calculation or estimation of reconciling items and the information is not available without unreasonable effort due to the uncertainty and potential variability of reconciling items, which are out of Cencora’s control and/or cannot be reasonably predicted, and the probable significance of which cannot be determined. In addition, because Cencora’s financial closing procedures for the full-year 2026 are not yet complete, our actual results may change as a result of such financial closing procedures, final adjustments, management's review of results, and other developments that may arise between now and the time financial results for the full-year 2026 are finalized.

列示该非GAAP财务指标是因为管理层使用非GAAP财务指标来评估Cencora的经营业绩、进行财务规划并确定激励性薪酬。因此,Cencora认为,列示该非GAAP财务指标为投资者提供了有用的补充信息,并有助于投资者进行进一步分析。所列示的非GAAP财务指标排除了管理层认为不能反映Cencora核心经营业绩的项目,因为此类项目不在Cencora的控制范围内,或本质上属于异常、非经营、不可预测、非经常性或非现金项目。

This press releases includes adjusted diluted earnings per share (“EPS”), which represents diluted earnings per share determined in accordance with GAAP adjusted for specific items including, the per share impact of: gains from antitrust litigation settlements; LIFO expense (credit); Türkiye highly inflationary impact; acquisition related intangibles amortization; litigation and opioid-related (credit) expenses, net; acquisition and divestiture-related deal and integration expenses; restructuring and other expenses, net; the impairment of assets, including goodwill; the remeasurement gain related to the acquisition of OneOncology; gain on equity method investment; and the gain (loss) on the currency remeasurement related to 2020 Swiss tax reform, in each case net of the tax effect calculated using the applicable effective tax rate for those items. In addition, the per share impact of certain discrete tax items and the per share impact of the amortization of deferred tax assets relating to 2020 Swiss tax reform are also excluded from adjusted diluted earnings per share. Management believes that this non-GAAP financial measure is useful to investors because it eliminates the per share impact of the items that are outside the control of the Company or that we consider to not be indicative of our ongoing operating performance due to their inherent unusual, non-operating, unpredictable, non-recurring, or non-cash nature.

Cencora不会在前瞻性基础上就该非GAAP财务指标提供与最可比GAAP财务指标的前瞻性调节表,因为公司无法对调节项目进行有意义或准确的计算或估计,且由于调节项目存在不确定性和潜在波动性,这些项目不在Cencora的控制范围内和/或无法合理预测,其可能的重要性也无法确定,因此不付出不合理的努力就无法获得相关信息。

此外,由于Cencora对2026年全年的财务结账程序尚未完成,我们的实际结果可能会因该等财务结账程序、最终调整、管理层对结果的审查以及从现在到2026年全年财务结果最终确定之间可能出现的其他进展而发生变化。

View source version on businesswire.com:

本新闻稿包含调整后稀释每股收益(“EPS”),即按照GAAP确定的稀释每股收益,并针对特定项目进行调整后的结果,包括以下各项的每股影响:反垄断诉讼和解收益;后进先出法费用(贷项);土耳其高通胀影响;与收购相关的无形资产摊销;诉讼及阿片类药物相关(贷项)费用净额;与收购和剥离相关的交易及整合费用;重组及其他费用净额;资产减值(包括商誉);与收购OneOncology相关的重新计量收益;权益法投资收益;以及与2020年瑞士税改相关的货币重新计量收益(亏损),上述每一项均按适用于这些项目的有效税率计算税后影响。

此外,某些离散税项的每股影响以及与2020年瑞士税改相关的递延所得税资产摊销的每股影响也从调整后稀释每股收益中剔除。管理层认为,这一非GAAP财务指标对投资者有用,因为它消除了公司无法控制的项目或我们认为因其固有的异常、非经营、不可预测、非经常性或非现金性质而不能反映我们持续经营业绩的项目的每股影响。

查看businesswire.com上的源版本:Bennett S. Murphy 高级副总裁,投资者关系与企业生产力 来源:Cencora

Bennett S. Murphy Senior Vice President, Investor Relations and Enterprise Productivity Source: Cencora

阅读媒体原文 ↗